Skip to main content
main-content

Respiratory

Respiratory

06-12-2018 | Asthma | News | Article

Tralokinumab does not reduce corticosteroid use in patients with severe asthma

Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.

Source:

Eur Respir J 2018; doi:10.1183/13993003.00948-2018

29-11-2018 | Respiratory | News | Article

Support for continued pirfenidone treatment in patients with IPF progression

Patients with idiopathic pulmonary fibrosis who have previously experienced disease progression whilst receiving pirfenidone may benefit from continued treatment with the antifibrotic agent, researchers report.

Source:

Chest 2018; doi:10.1016/j.chest.2018.11.008

22-11-2018 | Respiratory | News | Article

Inhaled hypertonic saline treatment feasible in young infants with cystic fibrosis

Preliminary findings from the phase II PRESIS trial suggest that preventative treatment with inhaled hypertonic saline is well tolerated and may improve lung clearance index in young infants with cystic fibrosis.

Source:

Am J Respir Crit Care Med 2018; doi:10.1164/rccm.201807-1203OC

15-11-2018 | Chronic obstructive pulmonary disease | News | Article

BREATHE programme improves outcomes for COPD patients

An intervention combining transitional care and self-management support after hospital discharge reduces the number of subsequent hospital visits and improves health-related quality of life among patients with chronic obstructive pulmonary disease, trial findings indicate.

Source:

JAMA 2018; doi:10.1001/jama.2018.17933
JAMA 2018; doi:10.1001/jama.2018.17508

08-11-2018 | Respiratory | News | Article

Benefits of nintedanib extend to patients with advanced IPF

Results of a real-world study suggest that nintedanib delays lung function decline in patients with idiopathic pulmonary fibrosis irrespective of disease severity.

Source:

Respir Res 2018; 19: 203

01-11-2018 | Asthma | News | Article

COLUMBA results support long-term use of mepolizumab in patients with severe asthma

The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.

Source:

J Allergy Clin Immunol 2018; doi:10.1016/j.jaci.2018.09.033

25-10-2018 | Respiratory | News | Article

Editor's pick

Triple combination CFTR modulator therapy shows potential for cystic fibrosis

Combination therapy with a next-generation cystic fibrosis transmembrane conductance regulator corrector, together with tezacaftor and ivacaftor, may be a promising treatment option for cystic fibrosis, suggest findings from two studies published in The New England Journal of Medicine.

Source:

NEJM 2018; doi:10.1056/NEJMoa1807120
NEJM 2018; doi:10.1056/NEJMoa1807119
NEJM 2018; doi:10.1056/NEJMe1811996

18-10-2018 | Respiratory | News | Article

TWICS results suggest no role for low-dose theophylline as add-on therapy in COPD

The addition of low-dose theophylline to inhaled corticosteroids does not reduce the risk of exacerbations among patients with chronic obstructive pulmonary disease, findings from the TWICS trial indicate.

Source:

JAMA 2018; 320: 1541–1542, 1548–1559

11-10-2018 | Asthma | News | Article

Changing inhaler device does not compromise asthma treatment effectiveness

Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.09.027

04-10-2018 | Respiratory | News | Article

Aspergillus positivity in young children with CF is not associated with bronchiectasis

In 5-year-old children with cystic fibrosis, positivity for Aspergillus species in bronchoalveolar lavage cultures is associated with air trapping but not with bronchiectasis or reduced lung function, indicates a longitudinal study.

Source:

Thorax 2018; doi:10.1136/thoraxjnl-2018-211550

03-10-2018 | Asthma | News | Article

Systemic corticosteroids reduce blood eosinophil counts

Systemic corticosteroid treatment reduces blood eosinophil counts and low levels are maintained for weeks after treatment is discontinued, show real-world data.

Source:

J Asthma 2018; doi:10.1080/02770903.2018.1502301

27-09-2018 | Respiratory | News | Article

Editor's pick

Long-term safety, efficacy profiles of nintedanib characterized in IPF patients

Results of the INPULSIS-ON extension study suggest that nintedanib has a manageable long-term safety profile and may slow the progression of idiopathic pulmonary fibrosis.

Source:

Lancet Respir Med 2018; doi:10.1016/S2213-2600(18)30339-4
Lancet Respir Med 2018; doi:10.1016/S2213-2600(18)30385-0

06-09-2018 | Asthma | News | Article

Single blood eosinophil measure predicts eosinophilic asthma

A single blood eosinophil count could predict persistent eosinophilia in patients with adult-onset asthma, study findings show.

Source:

Respir Med 2018; 141: 81–86

03-09-2018 | Asthma | News | Article

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

24-07-2018 | Asthma | News | Article

Editor's pick

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

04-07-2018 | Asthma | News | Article

Editor's pick

Asthma risk prediction score accounts for early treatment response

Researchers have developed a measure for predicting future asthma risk based on patient characteristics and current level of asthma control.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

20-06-2018 | Asthma | News | Article

Editor's pick

Good prognosis for patients with mild asthma

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

08-05-2018 | Asthma | News | Article

Editor's pick

Eosinophilia linked to lung function decline irrespective of asthma symptoms

High blood eosinophil counts are associated with airflow obstruction and lung function decline in patients with asthma, but also in people without respiratory symptoms, population-based study findings show.

Source:

Eur Respir J 2018; Advance online publication

04-05-2018 | Gastrointestinal cancer | News | Article

News in brief

GI cancer screening strategies warranted for cystic fibrosis patients

Cystic fibrosis is associated with an elevated risk for gastrointestinal cancer, find researchers who stress the need for developing a screening strategy in cystic fibrosis patients.

03-04-2018 | Respiratory | News | Article

Editor's pick

Airway type 2 inflammation refractory to corticosteroids in many severe asthma patients

Airway type 2 inflammation is not fully suppressed in around half of asthma patients despite receipt of inhaled corticosteroid treatment, study findings show.

Source:

J Allergy Clin Immunol 2018; Advance online publication

image credits